BRIEF published on 09/16/2026 at 07:35, 12 days 17 hours ago Nicox: NCX 470 data presentation at the 2026 AAOpt Congress Phase 3 Ophthalmology Nicox NCX 470 AAOpt Congress
PRESS RELEASE published on 09/16/2026 at 07:30, 12 days 17 hours ago Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026 Nicox presents key data on NCX 470 at AAOpt Annual Meeting 2026, focusing on glaucoma management. Details on clinical trials and future conference participation Clinical Trials Ophthalmology Nicox NCX 470 AAOpt
BRIEF published on 09/11/2026 at 07:35, 17 days 17 hours ago Nicox's NCX 470 NDA Accepted for Review in China Ophthalmology NCX 470 Ocumension Therapeutics China Market NDA Review
PRESS RELEASE published on 09/11/2026 at 07:30, 17 days 17 hours ago Nicox Announces NCX 470 NDA in China Accepted for Review Nicox announces acceptance of NCX 470 NDA in China by NMPA for review. Regulatory decision expected 12-18 months post-submission. Details on Ocumension and NCX 470 milestones China Nicox NCX 470 Regulatory Decision NMPA
BRIEF published on 09/02/2026 at 07:35, 26 days 17 hours ago Nicox Extends Its Cash Flow Horizon Thanks to NCX 470 Ophthalmology NDA Nicox NCX 470 Cash Flow Horizon
BRIEF published on 09/02/2026 at 07:35, 26 days 17 hours ago Nicox Announces Financial Stability Extension Financial Update Ophthalmology Nicox NCX 470 Cash Runway
PRESS RELEASE published on 09/02/2026 at 07:30, 26 days 17 hours ago Nicox Announces Extension of Cash Runway Nicox extends cash runway with estimated €8.4 million as of 31 August 2026, supporting operations beyond Q1 2028. NCX 470 U.S. NDA approval milestone could fund operations into 2029 Financial Update Ophthalmology Nicox NCX 470 Cash Runway
BRIEF published on 08/27/2026 at 07:35, 1 month 1 day ago Nicox: PDUFA date set for the NCX 470 in April 2027 FDA Glaucoma Nicox NCX 470 PDUFA
PRESS RELEASE published on 08/27/2026 at 07:30, 1 month 1 day ago Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma Nicox announces April 2027 PDUFA date for NCX 470 in Glaucoma. Positive results from Phase 3 trials pave the way for potential FDA approval and commercial launch in H2 2027 FDA Approval Glaucoma Nicox NCX 470 PDUFA Date
BRIEF published on 08/10/2026 at 07:35, 1 month 18 days ago Nicox's NCX 470 NDA Submitted in China Nicox Glaucoma Treatment NCX 470 Ocumension China NDA
Published on 09/29/2026 at 00:00, 1 hour 5 minutes ago Medicure Announces Completion of Enrollment in Its MEND-PNPO Phase 3 Clinical Trial
Published on 09/28/2026 at 23:00, 2 hours 5 minutes ago CORRECTION FROM SOURCE: Organto Foods Highlights Record First Half Results and Progress on Key Strategic Initiatives
Published on 09/28/2026 at 15:00, 10 hours 5 minutes ago Vox to Acquire Silver Royalty over the Sorby Hills Project in Australia
Published on 09/28/2026 at 14:45, 10 hours 20 minutes ago Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
Published on 09/28/2026 at 14:30, 10 hours 35 minutes ago Drilling at Cat Creek Intersects a Copper-Molybdenum Porphyry System Visible Molybdenite-Chalcopyrite Over Significant Core Widths
Published on 09/28/2026 at 22:14, 2 hours 51 minutes ago EQS-Adhoc: Extension of the Managing Directors' employment contracts of Carsten Cramer, Lars Ricken and Thomas Treß – Carsten Cramer appointed Chairman of the Management Board
Published on 09/28/2026 at 19:24, 5 hours 41 minutes ago EQS-Adhoc: Hapag-Lloyd further raises its earnings outlook for the current financial year
Published on 09/28/2026 at 18:00, 7 hours 5 minutes ago GEVELOT S.A.: Weekly declaration of share buybacks – 09/28/2026 (French only)
Published on 09/28/2026 at 17:53, 7 hours 12 minutes ago EQS-Adhoc: MeVis Medical Solutions AG: Forecast Adjustment for Fiscal Year 2025/2026
Published on 09/28/2026 at 17:49, 7 hours 15 minutes ago XTPL increased its global project pipeline in H1 2026, building more sales opportunities for subsequent periods
Published on 09/28/2026 at 17:54, 7 hours 10 minutes ago Reporting on share buyback transactions carried out between September 21 and September 25, 2026
Published on 09/28/2026 at 17:35, 7 hours 30 minutes ago Disclosure of transactions in own shares from September 21 to September 25, 2026
Published on 09/28/2026 at 08:02, 17 hours 3 minutes ago Saint-Gobain signs renewable electricity purchase agreement in the United Kingdom
